Tonix’s long COVID drug fails to meet mid-stage trial goal By Reuters

<p> <br />
</p>
<div>
<div>
<img decoding="async" alt="Tonix's long COVID drug fails to meet mid-stage trial goal" id="carouselImage" src="https://i-invdn-com.investing.com/trkd-images/LYNXMPEJ840FG_L.jpg" style="visibility:hidden" /><br />
<span>© Reuters. FILE PHOTO: The word “COVID-19” is reflected in a drop on a syringe needle in this illustration taken November 9, 2020. REUTERS/Dado Ruvic/Illustration/File Photo</span><br />
<i class="imgGrad"/>
</div>
<p>(Reuters) – Tonix Pharmaceuticals Holding Corp said on Tuesday its experimental drug failed to meet the primary goal in a mid-stage study for management of widespread muscle pain and tenderness associated with long COVID-19.</p>
<p>Shares of the company were down 12% in premarket trading. </p>
<p>The 63-patient study was designed to monitor the intensity of pain in patients who had long COVID and administered either the drug, TNX-102 SL, or placebo, but the trial failed to show improvement at week 14 of treatment, the company said.</p>
<p>However, the study showed that the drug helped reduce fatigue and improve sleep quality and cognitive function in the patients, the company said.</p>
<p>   Tonix intends to meet officials from the U.S. Food and Drug Administration in early 2024 to seek permission to conduct a late-stage trial that focuses on reducing fatigue in patients with long COVID, an illness with no approved drugs. </p>
</div>
<p><br />
<br /><a href="https://www.investing.com/news/stock-market-news/tonixs-long-covid-drug-fails-to-meet-midstage-trial-goal-3167530">Source link </a></p><p>The post <a href="https://forextraderhub.com/tonixs-long-covid-drug-fails-to-meet-mid-stage-trial-goal-by-reuters.html">Tonix’s long COVID drug fails to meet mid-stage trial goal By Reuters</a> first appeared on <a href="https://forextraderhub.com">Forex Trader Hub</a>.</p>